Circulating estrogens and postmenopausal ovarian and endometrial cancer risk among current hormone users in the Women's Health Initiative Observational Study

Author:

Trabert, Britton [ORCID]

Coburn, Sally B

Falk, Roni T

Manson, JoAnn E

Brinton, Louise A

Gass, Margery L

Kuller, Lewis H

Rohan, Thomas E

Pfeiffer, Ruth M

Qi, Lihong

Stefanick, Marcia L

Wentzensen, Nicolas

Anderson, Garnet L

Xu,Xia
Author Address

Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Drive, Bethesda, MD, 20892-9768, USA. britton.trabert@nih.gov., Department of Medicine, Brigham and Women 39;s Hospital, Harvard Medical School, Boston, MA, USA., Women 39;s Health Institute, Cleveland Clinic, Cleveland, OH, USA., Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA., Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA., Public Health Sciences, School of Medicine, UC Davis, Sacramento, CA, USA., Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA., Division of Public Health Sciences, Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Frederick National Laboratory for Cancer Research, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick, MD, USA.,

Abstract:

Purpose Menopausal hormone therapy (MHT) use induces alterations in circulating estrogens/estrogen metabolites, which may contribute to the altered risk of reproductive tract cancers among current users. Thus, the current study assessed associations between circulating estrogens/estrogen metabolites and ovarian and endometrial cancer risk among MHT users.

See More

Author Address